Comparative Pharmacology
Head-to-head clinical analysis: ACTRON versus ANAPROX DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTRON versus ANAPROX DS.
ACTRON vs ANAPROX DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
550 mg orally every 8 to 12 hours; maximum 1375 mg/day.
None Documented
None Documented
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 12–17 hours (mean ~14 hours), allowing twice-daily dosing. Steady-state is achieved after 4–5 doses.
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
Renal elimination of naproxen and its metabolites accounts for approximately 95% of the dose, with about 60% as unchanged drug and 40% as conjugated or hydroxylated metabolites. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
NSAID
NSAID